Analyze Diet

Topic:Vaccine

Vaccination in horses involves the administration of biological preparations designed to stimulate the equine immune system to recognize and combat specific pathogens. Vaccines are formulated to prevent or reduce the severity of infectious diseases that can affect equine health and performance. Common vaccines for horses include those for equine influenza, tetanus, equine herpesvirus, and West Nile virus. The administration schedule and type of vaccine can vary based on factors such as geographic location, age, and use of the horse. This page compiles peer-reviewed research studies and scholarly articles that explore the development, efficacy, and safety of vaccines in horses, as well as their impact on equine health management.
Efficacy of DNA vaccination against western equine encephalitis virus infection.
Vaccine    March 10, 2005   Volume 23, Issue 17-18 2280-2283 doi: 10.1016/j.vaccine.2005.01.032
Nagata LP, Hu WG, Masri SA, Rayner GA, Schmaltz FL, Das D, Wu J, Long MC, Chan C, Proll D, Jager S, Jebailey L, Suresh MR, Wong JP.The efficacy of a DNA vaccine against western equine encephalitis (WEE) infection in mice was evaluated. The 26S structural region was expressed, in vitro from an internal T7 promoter using a rabbit reticulysate transcription/translation system; and from a CMV promoter after transfection into Vero cell monolayers. The proteins synthesized were reactive with anti-WEE virus (WEEV) antibodies, both in western blot analysis and histochemical staining, respectively. When the DNA vaccine plasmid, pVHX-6, was administered intraepidermally to mice, followed by challenge in a lethal mouse model, the le...
Control and eradication of African horse sickness with vaccine.
Developments in biologicals    March 4, 2005   Volume 119 255-258 
Sánchez-Vizcaíno JM.African horse sickness (AHS) is an infectious but no-contagious viral disease of equidae with high mortality in horses. The disease is caused by an arthropod-borne double-stranded RNA virus within the genus Orbivirus of the family Reoviridae transmitted by at least two species of Culicoides. Nine different serotypes have been described. The nine serotypes of AHS have been described in eastern and southern Africa. Only AHS serotypes 9 and 4 have been found in West Africa from where they occasionally spread into countries surrounding the Mediterranean. Examples of outbreaks that have occurred ou...
The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine.
Veterinary therapeutics : research in applied veterinary medicine    February 19, 2005   Volume 5, Issue 4 251-257 
Grosenbaugh DA, Backus CS, Karaca K, Minke JM, Nordgren RM.A new recombinant West Nile virus (WNV) vaccine has been licensed for use in horses. Prior to the availability of the recombinant vaccine in 2004, the only equine WNV vaccine available on the market had been an inactivated vaccine. Since the recombinant vaccine only expresses selected viral genes, the question could be posed as to whether a single dose of the recombinant vaccine would be effective in producing an anamnestic serologic response in horses previously vaccinated with an inactivated WNV vaccine. In this study we demonstrate that vaccination of horses with a canarypox-vectored recomb...
Immune response to vaccines based upon the VapA protein of the horse pathogen, Rhodococcus equi, in a murine model.
International journal of medical microbiology : IJMM    February 18, 2005   Volume 294, Issue 7 437-445 doi: 10.1016/j.ijmm.2004.09.011
Vanniasinkam T, Barton MD, Heuzenroeder MW.Rhodococcus equi is a significant pathogen in foals predominantly causing a pyogranulomatous bronchopneumonia. Many vaccine candidates have been tested for the prevention of R. equi disease in foals. However, none of these have been developed for widespread commercial use. Previous studies have shown that a Th1 immune response is imperative for the protection of foals against R. equi disease. In this study a DNA and a protein vaccine based upon the well-characterised R. equi virulence-associated protein VapA were developed. The vaccines were tested in the BALB/c murine model and the results sh...
Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy.
Journal of virology    February 15, 2005   Volume 79, Issue 5 2666-2677 doi: 10.1128/JVI.79.5.2666-2677.2005
Craigo JK, Li F, Steckbeck JD, Durkin S, Howe L, Cook SJ, Issel C, Montelaro RC.Among the diverse experimental vaccines evaluated in various animal lentivirus models, live attenuated vaccines have proven to be the most effective, thus providing an important model for examining critical immune correlates of protective vaccine immunity. We previously reported that an experimental live attenuated vaccine for equine infectious anemia virus (EIAV), based on mutation of the viral S2 accessory gene, elicited protection from detectable infection by virulent virus challenge (F. Li et al., J. Virol. 77:7244-7253, 2003). To better understand the critical components of EIAV vaccine e...
Evaluation of administration of West Nile virus vaccine to pregnant broodmares.
Journal of the American Veterinary Medical Association    January 13, 2005   Volume 225, Issue 12 1894-1897 doi: 10.2460/javma.2004.225.1894
Vest DJ, Cohen ND, Berezowski CJ, Morehead JP, Blodgett GP, Blanchard TL.To determine whether administration of killed West Nile virus vaccine was associated with pregnancy loss among broodmares. Methods: Retrospective cohort study. Methods: 595 mares. Methods: Records of pregnant mares with known vaccination history from 4 farms were reviewed. Information obtained from 595 mares included mare's identification; farm; age; breed; reproductive status; last breeding date; date last known pregnant; vaccination date; age of conceptus at vaccination; vaccination during the early embryonic, early fetal, and late fetal periods; and whether an early embryonic death (EED), e...
Immunoglobulin M-capture enzyme-linked immunosorbent assay testing of cerebrospinal fluid and serum from horses exposed to west nile virus by vaccination or natural infection.
Journal of veterinary internal medicine    January 11, 2005   Volume 18, Issue 6 866-870 doi: 10.1892/0891-6640(2004)18<866:imeiat>2.0.co;2
Porter MB, Long M, Gosche DG, Schott HM, Hines MT, Rossano M, Sellon DC.The West Nile (WN) virus, present in the United States since 1999, is a cause of encephalomyelitis in birds, alligators, humans, and horses. No data exist regarding detection of anti-WN virus immunoglobins in equine cerebrospinal fluid (CSF). The aims of this study were to evaluate the blood-brain barrier (BBB) in WN virus-infected (WNE) horses, to compare diagnostic testing in serum and CSF, and to describe the immunoglobulin M (IgM) response in serum and CSF of vaccinated horses. CSF was collected from the lumbosacral (LS) space (n = 13) or the allanto-occipital (AO) space (n = 14) of WNE ho...
Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses.
American journal of veterinary research    November 30, 2004   Volume 65, Issue 11 1459-1462 doi: 10.2460/ajvr.2004.65.1459
Siger L, Bowen RA, Karaca K, Murray MJ, Gordy PW, Loosmore SM, Audonnet JC, Nordgren RM, Minke JM.To determine the onset of immunity after IM administration of a single dose of a recombinant canarypox virus vaccine against West Nile virus (WNV) in horses in a blind challenge trial. Methods: 20 mixed-breed horses. Methods: Horses with no prior exposure to WNV were randomly assigned to 1 of 2 groups (10 horses/group). In 1 group, a recombinant canarypox virus vaccine against WNV was administered to each horse once (day 0). The other 10 control horses were untreated. On day 26, 9 treated and 10 control horses were challenged via the bites of mosquitoes (Aedes albopictus) infected with WNV. Cl...
Rescue of disabled infectious single-cycle (DISC) equine arteritis virus by using complementing cell lines that express minor structural glycoproteins.
The Journal of general virology    November 24, 2004   Volume 85, Issue Pt 12 3709-3714 doi: 10.1099/vir.0.80443-0
Zevenhoven-Dobbe JC, Greve S, van Tol H, Spaan WJM, Snijder EJ.Equine arteritis virus (EAV) contains seven structural proteins that are all required to produce infectious progeny. Alphavirus-based expression vectors have been generated for each of these proteins to explore the possibilities for their constitutive expression in cell lines. This approach was successful for minor glycoproteins GP(2b), GP(3) and GP(4) and for the E protein. Subsequently, it was demonstrated that cell lines expressing these proteins could rescue EAV mutants that were disabled in the expression of the corresponding gene, resulting in the production of virus particles carrying t...
Outcome of tactile conditioning of neonates, or “imprint training” on selected handling measures in foals.
Veterinary journal (London, England : 1997)    October 27, 2004   Volume 168, Issue 3 252-258 doi: 10.1016/j.tvjl.2003.12.008
Spier SJ, Berger Pusterla J, Villarroel A, Pusterla N.Behavioural reactions to selected handling procedures were compared between conditioned, or imprint-trained, and untrained foals raised on the same farm. Nineteen randomly chosen healthy foals were imprint trained at birth and 24 h later (Group A). Twenty-one similar foals that were not imprint-trained served as age-matched controls (Group B). Training began within 10 min of birth and consisted of touch desensitization by gentle rubbing. Each tactile stimulus was repeated 30-50 times over 45-60 min, until the foal no longer resisted the procedure and appeared relaxed. The procedure was then re...
Evidence supporting the inclusion of strains from each of the two co-circulating lineages of H3N8 equine influenza virus in vaccines.
Vaccine    September 15, 2004   Volume 22, Issue 29-30 4101-4109 doi: 10.1016/j.vaccine.2004.02.048
Daly JM, Yates PJ, Newton JR, Park A, Henley W, Wood JL, Davis-Poynter N, Mumford JA.Two lineages of antigenically distinct equine influenza A H3N8 subtype viruses, American and European, co-circulate. Experiments were conducted in ponies to investigate the protection induced by vaccines containing virus from one lineage against challenge infection with homologous or heterologous virus. Regression analysis showed that vaccinated ponies with average pre-challenge single radial haemolysis (SRH) antibody levels (i.e. 45-190mm2) had a higher probability of becoming infected if they were vaccinated with virus heterologous to the challenge strain than if they were vaccinated with ho...
Evidence that use of an inactivated equine herpesvirus vaccine induces serum cytotoxicity affecting the equine arteritis virus neutralisation test.
Vaccine    September 15, 2004   Volume 22, Issue 29-30 4117-4123 doi: 10.1016/j.vaccine.2004.02.052
Newton JR, Geraghty RJ, Castillo-Olivares J, Cardwell JM, Mumford JA.Several laboratories worldwide have recently experienced problems related to serum cytotoxicity with the equine arteritis virus (EAV) neutralisation test (VN) when using Office International des Epizooties (OIE) reference laboratory prescribed rabbit kidney (RK-13) indicator cells. Cytotoxicity can be mistaken for viral cytopathic effect and has led to increasing difficulties in test interpretation, consequently causing disruption to both equine breeding and disease surveillance. Results from experimental and field-derived data suggest that this serum cytotoxicity is associated with use of a t...
Humoral response to West Nile virus vaccination in alpacas and llamas.
Journal of the American Veterinary Medical Association    August 27, 2004   Volume 225, Issue 3 414-416 doi: 10.2460/javma.2004.225.414
Kutzler MA, Baker RJ, Mattson DE.To determine humoral responses to an equine West Nile virus (WNV) vaccine in healthy alpacas and llamas and compare responses in alpacas and llamas with responses in horses. Methods: Clinical trial. Methods: 28 alpacas, 56 llamas, and 16 horses. Methods: Horses received 2 vaccinations at 4-week intervals, and alpacas and llamas received 3 vaccinations at 3-week intervals. Fifty-five llamas received a fourth vaccination 3 weeks after the third. Blood samples were collected immediately prior to each vaccination, 3 weeks after the last vaccination for alpacas and llamas, and 4 weeks after the las...
The effects of strain heterology on the epidemiology of equine influenza in a vaccinated population.
Proceedings. Biological sciences    August 13, 2004   Volume 271, Issue 1548 1547-1555 doi: 10.1098/rspb.2004.2766
Park AW, Wood JL, Daly JM, Newton JR, Glass K, Henley W, Mumford JA, Grenfell BT.We assess the effects of strain heterology (strains that are immunologically similar but not identical) on equine influenza in a vaccinated population. Using data relating to individual animals, for both homologous and heterologous vaccinees, we estimate distributions for the latent and infectious periods, quantify the risk of becoming infected in terms of the quantity of cross-reactive antibodies to a key surface protein of the virus (haemagglutinin) and estimate the probability of excreting virus (i.e. becoming infectious) given that infection has occurred. The data suggest that the infectio...
West Nile virus vaccines.
Expert opinion on biological therapy    July 23, 2004   Volume 4, Issue 8 1295-1305 doi: 10.1517/14712598.4.8.1295
Hall RA, Khromykh AA.West Nile virus (WNV) is a mosquito-borne flavivirus that is emerging as a global pathogen. In the last decade, virulent strains of the virus have been associated with significant outbreaks of human and animal disease in Europe, the Middle East and North America. Efforts to develop human and veterinary vaccines have taken both traditional and novel approaches. A formalin-inactivated whole virus vaccine has been approved for use in horses. DNA vaccines coding for the structural WNV proteins have also been assessed for veterinary use and have been found to be protective in mice, horses and birds...
Efficacy of a live equine herpesvirus-1 (EHV-1) strain C147 vaccine in foals with maternally-derived antibody: protection against EHV-1 infection.
Equine veterinary journal    July 16, 2004   Volume 36, Issue 5 447-451 doi: 10.2746/0425164044868332
Patel JR, Didlick S, Bateman H.Currently, there is no recommended immunoprophylaxis against febrile respiratory diseases due to equine herpesvirus-1 (EHV-1) and -4 (EHV-4) in horses below age 5-6 months. This is because of interference by maternally-derived antibody (MDA) of vaccines. Objective: Unweaned equine foals are an important reservoir of EHV-1 transmission; therefore, we experimentally assessed the efficacy of a live EHV-1 vaccine in foals age 1.4-3.5 months with MDA. Methods: Following vaccination and challenge, parameters assessed were virus shedding in nasal mucus, leucocyte-associated viraemia, circulating viru...
Current perspectives on control of equine influenza.
Veterinary research    July 9, 2004   Volume 35, Issue 4 411-423 doi: 10.1051/vetres:2004023
Daly JM, Newton JR, Mumford JA.Influenza A viruses of the H3N8 subtype are a major cause of respiratory disease in horses. Subclinical infection with virus shedding can occur in vaccinated horses, particularly where there is a mismatch between the vaccine strains and the virus strains circulating in the field. Such infections contribute to the spread of the disease. Rapid diagnostic techniques are available for detection of virus antigen and can be used as an aid in control programmes. Improvements have been made to methods of standardising inactivated virus vaccines, and a direct relationship between vaccine potency measur...
DNA vaccines–back in the saddle again?
Nature biotechnology    July 2, 2004   Volume 22, Issue 7 799-801 doi: 10.1038/nbt0704-799
Powell K.A promising new horse vaccine may reignite enthusiasm for DNA vaccine technology in designing prophylactics against infectious disease. Kendall Powell reports.
Detection of EHV-1 and EHV-4 DNA in unweaned Thoroughbred foals from vaccinated mares on a large stud farm.
Equine veterinary journal    May 28, 2004   Volume 36, Issue 4 341-345 doi: 10.2746/0425164044890634
Foote CE, Love DN, Gilkerson JR, Whalley JM.A silent cycle of equine herpesvirus 1 infection has been described following epidemiological studies in unvaccinated mares and foals. In 1997, an inactivated whole virus EHV-1 and EHV-4 vaccine was released commercially in Australia and used on many stud farms. However, it was not known what effect vaccination might have on the cycle of infection of EHV-1. Objective: To investigate whether EHV-1 and EHV-4 could be detected in young foals from vaccinated mares. Methods: Nasal and blood samples were tested by PCR and ELISA after collection from 237 unvaccinated, unweaned foals and vaccinated an...
Evaluation of immune responses in horses immunized using a killed Sarcocystis neurona vaccine.
Veterinary therapeutics : research in applied veterinary medicine    May 20, 2004   Volume 5, Issue 1 34-42 
Marsh AE, Lakritz J, Johnson PJ, Miller MA, Chiang YW, Chu HJ.Clinically normal horses developed cellular immunity to Sarcocystis neurona following IM vaccination with a commercial killed S. neurona vaccine, as indicated by the development of measurable anti-S. neurona IgG antibodies and additional intradermal skin testing. Large-scale independent assessments of the vaccine's performance and safety are in progress under field conditions. The next step in the evaluation of this vaccine would be to attempt experimental challenge after a reproducible reliable equine model of S. neurona encephalitis has been established that allows for reisolation of the pat...
Serologic responses to eastern and western equine encephalomyelitis vaccination in previously vaccinated horses.
Veterinary therapeutics : research in applied veterinary medicine    May 12, 2004   Volume 4, Issue 3 242-248 
Waldridge BM, Wenzel JG, Ellis AC, Rowe-Morton SE, Bridges ER, D'Andrea G, Wint R.A prospective study was performed to determine the serologic response of previously vaccinated horses to revaccination against eastern and western equine encephalomyelitis (EEE and WEE). Horses responded variably to each antigen, and some horses had low or undetectable antibodies 6 months after vaccination. Some horses did not develop increasing titers to EEE or WEE despite recent vaccination. Geometric mean titers peaked 2 weeks after revaccination and were significantly increased from before revaccination. Except for one horse, EEE:WEE titer ratios ranged from 0.25 to 2.0. Regular vaccinatio...
Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge.
Archives of virology. Supplementum    May 4, 2004   Issue 18 221-230 doi: 10.1007/978-3-7091-0572-6_20
Minke JM, Siger L, Karaca K, Austgen L, Gordy P, Bowen R, Renshaw RW, Loosmore S, Audonnet JC, Nordgren B.An ALVAC (canarypoxvirus)-based recombinant (vCP2017) expressing the prM and E genes derived from a 1999 New York isolate of West Nile virus (WNV) was constructed and assessed for its protective efficacy in horses in two different experiments. In the first trial, a dose titration study was conducted to evaluate both serum neutralising antibody responses to WNV and duration of immunity. In the second trial the onset of protection was determined. Twenty-eight adult horses received two doses of vCP2017 administered intramuscularly at 5-week intervals and sixteen horses comprised age-matched non-v...
Seroprevalence of equine herpesvirus 1 in mares and foals on a large Hunter Valley stud farm in years pre- and postvaccination.
Australian veterinary journal    April 16, 2004   Volume 81, Issue 5 283-288 doi: 10.1111/j.1751-0813.2003.tb12576.x
Foote CE, Gilkerson JR, Whalley JM, Love DN.To examine the prevalence of equine herpesvirus 1 antibody in mares and foals on a large Hunter Valley Thoroughbred stud farm in New South Wales before and after the introduction of an inactivated whole virus vaccine. Methods: Cross-sectional serological surveys performed in February 1995 and 2000 to determine the prevalence of EHV-1 antibody-positive mares and foals. A further cross-sectional survey was carried out in 2001 to complement the 2000 data. Methods: Two hundred and twenty-nine mares and their foals were sampled in 1995 and 236 mares and their foals were sampled in 2000. The study p...
Prevalence of antibody to Japanese encephalitis virus nonstructural 1 protein among racehorses in Japan: indication of natural infection and need for continuous vaccination.
Vaccine    March 9, 2004   Volume 22, Issue 9-10 1097-1103 doi: 10.1016/j.vaccine.2003.10.001
Konishi E, Shoda M, Kondo T.Japanese encephalitis virus (JEV) causes fatal diseases in equines as well as humans. In Japan, racehorses are vaccinated with inactivated JE vaccine every year and no equine JE cases have been reported since 1986. However, the current reduction in JEV activity in nature has raised an argument against the requirement of continuous vaccination. Here, we studied natural infection rates in racehorses to address the issue. To identify naturally-infected individuals from vaccinated populations, we used an immunostaining method for detecting antibodies to JEV nonstructural 1 (NS1) protein. A total o...
Updating equine influenza strains in a combined equine influenza and herpesvirus vaccine.
Veterinary journal (London, England : 1997)    February 21, 2004   Volume 167, Issue 2 118-120 doi: 10.1016/S1090-0233(03)00034-0
Cullinane AA.No abstract available
Efficacy and duration of immunity of a combined equine influenza and equine herpesvirus vaccine against challenge with an American-like equine influenza virus (A/equi-2/Kentucky/95).
Veterinary journal (London, England : 1997)    February 21, 2004   Volume 167, Issue 2 150-157 doi: 10.1016/S1090-0233(03)00028-5
Heldens JG, Pouwels HG, van Loon AA.It has been recommended that modern equine influenza vaccines should contain an A/equi-1 strain and A/equi-2 strains of the American and European-like subtype. We describe here the efficacy of a modern updated inactivated equine influenza-herpesvirus combination vaccine against challenge with a recent American-like isolate of equine influenza (A/equine-2/Kentucky/95 (H3N8). The vaccine contains inactivated Influenza strains A-equine-1/Prague'56, A-equine-2/Newmarket-1/'93 (American lineage) and A-equine-2/ Newmarket-2/93 (Eurasian lineage) and inactivated EHV-1 strain RacH and EHV-4 strain V22...
Sarcocystis neurona-specific immunoglobulin G in the serum and cerebrospinal fluid of horses administered S neurona vaccine.
Journal of veterinary internal medicine    February 10, 2004   Volume 18, Issue 1 98-103 doi: 10.1892/0891-6640(2004)18<98:snigit>2.0.co;2
Witonsky S, Morrow JK, Leger C, Dascanio J, Buechner-Maxwell V, Palmer W, Kline K, Cook A.A vaccine against Sarcocystis neurona, which induces equine protozoal myeloencephalitis (EPM), has received conditional licensure in the United States. A major concern is whether the immunoglobulin G (IgG) response elicited by the vaccine will compromise the use of Western blotting (WB) as a diagnostic tool in vaccinated horses with neurologic disease. Our goals were to determine if vaccination (1) causes seroconversion: (2) causes at least a transient increase in S neurona-specific IgG in the cerebrospinal fluid (CSF); and (3) induces an IgG response that can be differentiated from that induc...
Equine vaccine for West Nile virus.
Developments in biologicals    December 18, 2003   Volume 114 221-227 
Ng T, Hathaway D, Jennings N, Champ D, Chiang YW, Chu HJ.To meet the urgent need of controlling West Nile virus (WNV) infection in the equine population, we have developed a killed WNV vaccine. A dose titration study in horses was first conducted to evaluate serum neutralization antibody responses against WNV in these animals. Horses were vaccinated intramuscularly twice with the test vaccine at low, medium and high dose, three weeks apart. Serum samples were collected periodically and were measured for serum neutralizing antibody using a plaque reduction neutralization test. Significant increases in serum neutralizing antibody were detected in all ...
Lyme borreliosis.
Journal of the American Veterinary Medical Association    November 19, 2003   Volume 223, Issue 9 1261-1270 doi: 10.2460/javma.2003.223.1261
Fritz CL, Kjemtrup AM.Despite more than 25 years' experience with Lyme borreliosis, much remains to be learned about this complex zoonosis. Practicing veterinarians, particularly those in the northeastern and upper midwestern states, where Lyme borreliosis is highly endemic, should be familiar with the ecologic features and typical clinical signs of Lyme borreliosis. Interpretation of signs and serologic test results should be made with consideration of the regional prevalence of Lyme borreliosis and the animal's opportunity for exposure to infected Ixodes spp. The availability of recently marketed topical acaracid...
APHIS: West Nile virus vaccine safe for use.
Journal of the American Veterinary Medical Association    August 22, 2003   Volume 223, Issue 4 416-418 
Kahler SC.No abstract available
1 16 17 18 19 20 29